Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) is expected to post its results before the market opens on Wednesday, September 2nd. Analysts expect the company to announce earnings of ($3.75) per share and revenue of $0.40 million for the quarter.
Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($5.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.40 million.
Jupiter Neurosciences Price Performance
Shares of NASDAQ JUNS opened at $3.54 on Tuesday. The company has a market capitalization of $3.22 million, a price-to-earnings ratio of -0.19 and a beta of 1.99. The business has a 50-day moving average of $10.18 and a two-hundred day moving average of $21.84. Jupiter Neurosciences has a 1 year low of $2.88 and a 1 year high of $137.96.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on JUNS
Institutional Trading of Jupiter Neurosciences
A hedge fund recently raised its position in Jupiter Neurosciences stock. Geode Capital Management LLC lifted its position in Jupiter Neurosciences, Inc. (NASDAQ:JUNS – Free Report) by 27.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 132,641 shares of the company’s stock after purchasing an additional 28,826 shares during the quarter. Geode Capital Management LLC owned approximately 0.39% of Jupiter Neurosciences worth $135,000 at the end of the most recent quarter.
About Jupiter Neurosciences
Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.
Featured Stories
- Five stocks we like better than Jupiter Neurosciences
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Jupiter Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
